BuvatJ, Boujaoudé G. Update of testosterone therapy in the aging male. Submitted for publication.
2.
GruenewaldD.A., MatsumotoA.M.Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr, 2003; 51:101–115.
3.
LiuP.Y., SwerdloffR.S., VeldhuisJ.D.The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab, 2004; 89:4789–4796.
4.
LunenfeldB., SaadF., HoeslC.E.ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male, 2005; 8:59–74.
5.
BrillK.T., WeltmanA.L., GentiliA., PatrieJ.T., FryburgD.A., HanksJ.B., et al.Single and combined effects of Growth Hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover and muscle gene expression in healthy older men. J Clin Endocrinol Metab, 2002; 87:5649–5657.
6.
CrawfordB.A.L., LiuP.Y., KeanM.T., BleaselJ.F., HandelsmanD.J.Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab, 2003; 88:3167–3176.
7.
ShoresM.M., MoceriV.M., SloanK.L., MatsumotoA.M., KivlahanD.R.Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry, 2005; 66:7–14.
8.
SeidmanS.N., AraujoA.B., RooseS.P., McKinlayJ.B.Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry, 2001; 50:371–376.
9.
AversaA., IsidoriA.M., SperaG., LenziA., FabbriA.Androgens improve cavernous vasodilation and respons to sildenafil in patients with erectile dysfunction. Clin Endocrinol, 2003; 58:632–638.
10.
ShabsighR., KaufmanJ.M., SteidleC., Padma-NathanH.Randomized study of tesosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol, 2004; 172:658–663.
11.
BuvatJ., LemaireA.Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol, 1997; 158:1764–1767.
12.
MoralesA., BuvatJ., GoorenL.J., GuayM.D., KaufmanJ.M., TanH.M., et al.Endocrine aspects of sexual dysfunction in men. J Sex Med, 2004; 1:69–81.
13.
LiuP.Y., DeathA.K., HandelsmanD.J.Androgens and cardiovascular disease. Endocr Rev, 2003; 24:313–340.
14.
WuF.C., von EckardsteinA.Androgens and coronary artery disease. Endocr Rev, 2003; 24:183–217.
15.
HsingA.W.Hormones and prostate cancer: what's next?. Epidemiol Rev, 2001; 23:42–56.
16.
ShatzlG., MadersbacherS., HaitelA., GsurA., PreyerM., HaidingerG., et al.Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol, 2003; 169:1312–1315.
17.
RhodenE.L., MorgentalerA.Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: result of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol, 2003; 170:2348–2351.
18.
KaufmanJ.M., GraydonR.J.Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol, 2004; 172:920–922.
19.
ZittmannM., DepenbuschM., GromollJ., NieschlagE.Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longtudinal pharmacogenetic study. J Clin Endocrinol Metab, 2003; 88:2049–2054.
20.
KrithivasK., YurgalevitchS.M., MohrB.A., WilcoxC.J., BatterS.J., BrownM., et al.Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol, 1999; 162:137–142.
21.
NieschlagE., SwerdloffR., BehreH.M., GoorenL.J., KaufmanJ.M., LegrosJ.J., et al.Investigations, treatment and monitoring of late-onset hypogonadism in males. Aging Male, 2005; 8:56–58.
